BUSINESS OVERVIEW INOVIQ Ltd (ASX:IIQ) is a biotechnology company pioneering next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and specific EXONET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and earlystage exosome therapeutics for solid tumours. HIGHLIGHTS INOVIQ made significant progress during financial year 2024 and up to the date of this report. The Company secured a global distribution partnership for its in-market EXO-NET® exosome research tools, advanced its cancer diagnostics pipeline towards key development milestones, progressed its research-stage exosome therapeutics program, expanded its Board and completed a capital raising. 4 INOVIQ Limited Commercial › Global supply and distribution agreement for EXO-NET® signed with leading US life sciences company, Promega Corporation › First EXO-NET order received from Promega under distribution agreement › INOVIQ and ResearchDx signed a license and supply agreement for INOVIQ’s EXO-NET panexosome capture product to provide EXO-NET services in the US › Multiple EXO-NET (Pan and Neuro) feasibility studies ongoing with pharma/diagnostic companies for potential exosome diagnostics › Intellectual property for exosome platform expanded with new patent applications protecting NEURO-NET brain-derived exosome isolation and EXOACE isolation of therapeutic exosomes Review of Operations We are pleased to present the Group’s Annual Report for the financial year ended 30 June 2024 and provide an update on further strategic and operational progress since year end.
RkJQdWJsaXNoZXIy MjE2NDg3